Drug Trial Radar · NCT07417449
Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEP
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Apr 1, 2026
Primary completion
Nov 30, 2026
Study completion Jan 1, 2027
Sponsor
- Lead sponsor
- Ankara City Hospital BilkentAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 18, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- Male only, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to investigate the effects of long-term dutasteride use (a 5-alpha reductase inhibitor) on surgical outcomes in patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP) for benign prostatic hyperplasia (BPH). While some studies suggest that short-term use of these medications can reduce bleeding during surgery, there is limited data on the impact of chronic, long-term use (at least 6 months) specifically during the HoLEP procedure. The researchers will retrospectively analyze patient records to compare two groups: those who used dutasteride for 6 months or longer before surgery, and those who did not use any 5-alpha reductase inhibitors. The primary focus is to determine whether long-term dutasteride treatment leads to a significant difference in surgical bleeding (measured by hemoglobin drop), operation time, and the efficiency of removing prostate tissue (morcellation). The findings will help surgeons better understand how preoperative medication history influences the technical aspects of HoLEP surgery.
Conditions
- Prostatic Hyperplasia, Benign
Interventions
DutasterideDrug
Patients in the study group received 0.5 mg/day of dutasteride for at least 6 months before surgery as part of their routine BPH treatment.
Holmium Laser Enucleation of the Prostate (HoLEP)Procedure
Standard HoLEP procedure performed for the surgical treatment of benign prostatic hyperplasia.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Hemoglobin Levels (Hemoglobin Drop)Time frame: From the time of hospital admission (preoperative) up to 24 hours after surgery.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ankara Bilkent City Hospital
Ankara, Universiteler, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.